Bioharvest Sciences Inc Quick Ratio (BHST) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Bioharvest Sciences Inc   (BHST)

Bioharvest Sciences Inc 's Quick Ratio

BHST's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Bioharvest Sciences Inc 's Cash & cash equivalent grew by 100 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Bioharvest Sciences Inc 's Quick Ratio to 14.57, above Bioharvest Sciences Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 194 other companies have achieved higher Quick Ratio than Bioharvest Sciences Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 693.

Explain Quick Ratio?
How much Cash & cash equivalents BHST´s has?
What are BHST´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BHST Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Y / Y Current Liabilities Change -60.08 % -75.47 % - - -
Y / Y Cash & cash equivalent Change 1826.78 % 329.97 % - - -
Quick Ratio MRQ 14.57 3.98 3.98 3.98 0.3
BHST's Total Ranking # 693 # # # #
Seq. Current Liabilities Change -45.39 % 0 % 0 % -26.89 % -66.45 %
Seq. Cash & cash equivalent Change 100 % 0 % 0 % 863.39 % -55.37 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 195
Healthcare Sector # 321
Overall Market # 693


Quick Ratio Statistics
High Average Low
3.98 3.98 3.98
(Dec 31 2025)  




Financial Statements
Bioharvest Sciences Inc 's Current Liabilities $ 3 Millions Visit BHST's Balance sheet
Bioharvest Sciences Inc 's Cash & cash equivalent $ 46 Millions Visit BHST's Balance sheet
Source of BHST's Sales Visit BHST's Sales by Geography


Cumulative Bioharvest Sciences Inc 's Quick Ratio

BHST's Quick Ratio for the trailling 12 Months

BHST Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -34.86 % 7.15 % - - -
Y / Y Cash & cash equivalent TTM Growth 1386.44 % 1234.55 % - - -
Quick Ratio TTM 5.61 2.83 1.25 0.83 0.25
Total Ranking TTM # 4086 # # # #
Seq. Current Liabilities TTM Growth -18.81 % -41.33 % 15.52 % 18.37 % 33.55 %
Seq. Cash & cash equivalent TTM Growth 61.09 % 32.85 % 74.83 % 297.29 % 44.63 %

Quick ratio ranking by company, industry and sector >> Back to BHST Financial Strength Comparisons >> Go to Compare BHST Quick Ratio to its Competitors

On the trailing twelve months basis BHST Cash & cash equivalent more than doubled by 1826.78 % in Q4 2025 year on year, while Current Liabilities dropped to $3 millions, this led to increase in in Bioharvest Sciences Inc 's Quick Ratio to 5.61, Quick Ratio remained below BHST average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 467 other companies have achieved higher Quick Ratio than Bioharvest Sciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 4086.

Explain Quick Ratio?
How much Cash & cash equivalents BHST´s has?
What are BHST´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 468
Healthcare Sector # 949
Within the Market # 4086


trailing twelve months Quick Ratio Statistics
High Average Low
5.99 5.99 5.99
(Dec 31 2025)  




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Janux Therapeutics Inc   38.67 $ 966.567  Millions$ 24.997  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Curanex Pharmaceuticals Inc  36.30 $ 4.973  Millions$ 0.137  Millions
Prothena Corporation Public Limited Company  36.01 $ 307.531  Millions$ 8.539  Millions
Minerva Neurosciences Inc   35.93 $ 82.302  Millions$ 2.290  Millions
Ligand Pharmaceuticals Incorporated  33.03 $ 1,236.811  Millions$ 37.447  Millions
Roivant Sciences Ltd   32.71 $ 4,886.891  Millions$ 149.411  Millions
Disc Medicine Inc   32.19 $ 791.152  Millions$ 24.579  Millions
Fulcrum Therapeutics Inc   27.00 $ 352.306  Millions$ 13.048  Millions
Contineum Therapeutics Inc   26.98 $ 262.896  Millions$ 9.744  Millions
Rapport Therapeutics Inc   25.75 $ 490.539  Millions$ 19.049  Millions
Upstream Bio Inc   25.39 $ 341.509  Millions$ 13.452  Millions
Mbx Biosciences Inc   24.12 $ 373.705  Millions$ 15.495  Millions
Structure Therapeutics Inc   22.85 $ 1,446.197  Millions$ 63.285  Millions
Monopar Therapeutics Inc   22.61 $ 61.834  Millions$ 2.735  Millions
Kairos Pharma Ltd   22.57 $ 4.491  Millions$ 0.199  Millions
Sagimet Biosciences inc   22.52 $ 113.124  Millions$ 5.023  Millions
Dyne Therapeutics Inc   21.94 $ 1,110.562  Millions$ 50.625  Millions
Arca Biopharma Inc  21.92 $ 337.044  Millions$ 15.374  Millions
Aprea Therapeutics Inc   20.46 $ 14.599  Millions$ 0.714  Millions
Spyre Therapeutics Inc   20.40 $ 1,197.428  Millions$ 58.685  Millions
Jade Biosciences Inc   20.33 $ 336.158  Millions$ 16.539  Millions
Siga Technologies Inc  19.99 $ 154.966  Millions$ 7.753  Millions
Trevi Therapeutics Inc   19.94 $ 188.260  Millions$ 9.442  Millions
Edgewise Therapeutics inc   19.37 $ 530.109  Millions$ 27.370  Millions
Maplight Therapeutics Inc   18.80 $ 305.103  Millions$ 16.229  Millions
Kezar Life Sciences Inc   16.92 $ 71.878  Millions$ 4.248  Millions
Stoke Therapeutics Inc   16.90 $ 284.670  Millions$ 16.840  Millions
Design Therapeutics Inc   16.84 $ 219.845  Millions$ 13.055  Millions
Neurogene Inc   16.39 $ 269.013  Millions$ 16.411  Millions

Date modified: 2026-07-07T09:31:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.